Promising Pathways for Blood Biomarkers: Breaking Down Bio-Hermes Study

In 2020, Phyllis was placed as an executive-on-loan to the World Economic Forum-commissioned Davos Alzheimer’s Collaborative (DAC), where she has served as the visionary and founder of the Healthcare System Preparedness program. DAC is a global multi-stakeholder partnership of organizations aimed at mobilizing the world against Alzheimer’s disease, with the specific focus of ensuring that health systems are prepared to embrace innovation and better care for our global aging population.

Phyllis has a BA in Economics from DePauw University, an MBA from Stanford University and a PhD in Global Public Health Leadership from Indiana University. Phyllis is a current member of the World Dementia Council and serves on many boards and advisory committees in the field. Phyllis is passionate about Alzheimer’s advocacy and brain health so that other boys do not have to grow up without their grandfathers’ presence as her sons did.

Read Less...

He is commonly lauded for his leadership skills and working relationships, internationally recognized for his contributions to the field and at the age of 36 was on Clarivate’s list of the world’s most highly cited researchers. Dr. Ashton leads harmonization efforts for fluid biomarkers for the Alzheimer’s Association and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) to achieve biomarker-common results across the globe.

Dr. Ashton’s recent appointment as the Senior Director of the Banner Health Biomarker Program includes two new state-of-the-art laboratories on the BSHRI campus. His Biomarker Discovery Laboratory will develop, optimize and validate new spinal fluid and blood tests for Alzheimer’s disease and other neurodegenerative and cerebrovascular diseases. The tests include remote blood tests that can be administered at home, setting the stage for their widespread use in research studies, treatment and prevention trials, and their use in the clinical setting.

His Biomarker Assessment Laboratory will provide a state-of-the-art resource for the performance of rapid, rigorous and high-throughput resource biological fluid assays for academic and industry researchers to advance the scientific understanding, treatment and prevention of neurodegenerative and cerebrovascular diseases and leverage the latest immuno- and mass spectroscopy platforms, reagents and methods.

Read Less...

Her time at Biogen followed 20 years of experience at Eli Lilly and Company where she served as Asset Manager for Chorus, an autonomous early-phase clinical development organization within Lilly. Dr. Nisenbaum also served as a Research Fellow and neuroscience lead in tailored therapeutics, translational medicine and preclinical drug discovery. Prior to joining the biotechnology field, Dr. Nisenbaum received a Fulbright Scholarship to study in Cologne, Germany. She then completed her PhD in Neuroscience in 1991 at the University of Pittsburgh and transitioned to industry after completing postdoctoral training at the National Institutes of Health (NIH), the University of Tennessee College of Medicine and a faculty position in Physiology and Neurobiology at the University of Connecticut.

Throughout her career, Dr. Nisenbaum has contributed to the discovery and development of more than 15 novel therapeutics, bringing three molecules for FDA approval. She has also authored over 35 publications in peer-reviewed scientific journals.

Read Less...